Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects
Completed
Amgen
Phase 2
2011-07-28
The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG
145), compared with ezetimibe, on percent change from baseline in low-density lipoprotein
cholesterol (LDL-C) in patients with hypercholesterolemia unable to tolerate an effective
dose of a statin.
Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels
Completed
Amgen
Phase 2
2011-07-06
The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG
145) every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on the percent change
from baseline in LDL-C when used as monotherapy in adults with hypercholesterolemia.
Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
Completed
Amgen
Phase 3
2012-01-05
To evaluate the efficacy, safety, and tolerability of 52 weeks of subcutaneous (SC)
evolocumab (AMG 145) compared with placebo when added to assigned background lipid-lowering
therapy.
Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
Completed
Amgen
Phase 3
2013-01-21
The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneous (SC)
monotherapy every 2 weeks (Q2W) and monthly (QM), compared with placebo and ezetimibe, on
percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in adults with a
10-year Framingham risk score of 10% or less.
LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
Completed
Amgen
Phase 3
2013-01-15
The primary objective was to evaluate the effect of 12 weeks of evolocumab administered
subcutaneously every 2 weeks (Q2W) and monthly (QM) when used in combination with a statin,
compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol
(LDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia.
This preview shows a limited data set Subscribe for full access, or try a Trial
Evolocumab: Clinical Trials Update, Market Analysis, and Future Projections
Last updated: January 25, 2026
Executive Summary
Evolocumab, a monoclonal antibody developed by Amgen, is a PCSK9 inhibitor authorized for treatment of hypercholesterolemia and cardiovascular risk reduction. This report consolidates recent clinical trial developments, assesses current market dynamics, and projects future trends through 2030. Evolocumab remains a significant player in lipid-lowering therapies, with ongoing trials expanding its indications. The market faces competitive pressures from alternative therapies and emerging biosimilars, but continued innovation and regulatory support suggest sustained growth.
Results from FOURIER trial published; additional safety data ongoing
Phase IV
2
Post-marketing safety, cardiovascular benefits in diverse populations
Ongoing
Real-world effectiveness studies initiated
Investigational
3
New indications, combination therapies, long-term effects
Preclinical or early clinical trials
Biodistribution and pharmacokinetic studies underway
Key Clinical Trials:
FOURIER Trial (NCT01663402): A pivotal Phase III trial with over 27,000 patients assessing cardiovascular outcomes. Published (2017) demonstrated a 15% reduction in major cardiovascular events versus placebo (Sabatine et al., New England Journal of Medicine).
PEGASUS-TIMI 54 (NCT02433771): Evaluated evolocumab in secondary prevention; confirmed reductions in LDL-C by 59% and improved cardiovascular outcomes.
Long-Term Safety & Efficacy Studies: Recent extensions confirm durability of LDL-C reduction and acceptable safety profile over 4 years; adverse event rates comparable to placebo.
Emerging Directions
Combination Therapies: Ongoing trials combining evolocumab with other lipid-lowering agents, such as ezetimibe, to further optimize LDL-C reduction.
Expanded Indications: Investigations into use for familial hypercholesterolemia, statin intolerance, and nonalcoholic fatty liver disease (NAFLD).
Market Analysis
Market Size and Growth
Parameter
Value
Source
2022 Global Market (USD)
$8.2 billion
[1]
Compound Annual Growth Rate (CAGR)
9.3% (2022-2030)
[2]
Estimated Market (2030)
$17.5 billion
[2]
Key Market Drivers
Rising prevalence of hyperlipidemia globally.
Increasing awareness of cardiovascular disease prevention.
Expanded insurance coverage and reimbursement policies.
Evolving clinical guidelines endorsing PCSK9 inhibitors as adjunct therapies.
Launch of biosimilars and differentiated formulations.
Competitive Landscape
Player
Product
Market Share (2022)
Key Differentiator
Status
Amgen
Evolocumab (Repatha)
~55%
Proven long-term outcomes, broad approval
Market leader
Regeneron/Sanofi
Alirocumab (Praluent)
~30%
Competitive efficacy, established approvals
Major competitor
Novartis
Inclisiran (Leqvio)
~10%
Unique siRNA mechanism, less frequent dosing
Emerging competitor
Biosimilar firms
Various (biosimilars)
~5%
Lower price points, regulatory approval in select regions
Growing at risk of biosimilar entry
Pricing and Reimbursement
Region
Average Annual Cost per Patient (USD)
Coverage Status
Notes
U.S.
$7,000 - $8,400
Broad insurance coverage, increasing access
CMS includes in Medicare Part D via negotiated agreements
Implication: The market is expected to grow at a CAGR of approximately 9.3%, driven by an aging population and breakthroughs in pharmacotherapy.
Comparison with Competitors
Parameter
Evolocumab
Alirocumab
Inclisiran
Biosimilars
Mechanism
Monoclonal antibody
Monoclonal antibody
siRNA-based
Various, lower cost
Dosing Frequency
Biweekly or monthly
Biweekly
Twice yearly
N/A
Approval Year
2015 (FDA)
2015 (FDA)
2020 (EMA)
202X (pending)
Long-term Outcomes Data
Yes
Yes
Limited
Limited/Under clinical trials
Challenges and Opportunities
Challenges
Competitive Intensification: Biosimilars and new agents threaten market share.
Pricing and Reimbursement Constraints: Increasing pressure to lower costs.
Patient Adherence: Subcutaneous injections may impact compliance; longer dosing intervals are preferred.
Opportunities
New Indications: Expanding into settings such as NAFLD and stroke prevention.
Combination Therapies: Synergistic effects with other lipid-lowering agents.
Personalized Medicine: Tailoring therapy based on genetic profiles.
FAQs
What is the primary mechanism of evolocumab?
Evolocumab inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), enhancing LDL receptor recycling and increasing clearance of LDL cholesterol.
What are the key clinical benefits demonstrated by evolocumab?
Significant LDL-C reduction (~60%) and reduction in major adverse cardiovascular events, with safety profiles comparable to standard treatments.
How does evolocumab compare to other PCSK9 inhibitors?
Efficacy is comparable; however, dosing frequency and formulation infrastructure differ, with evolocumab offering flexibility through biweekly or monthly injections.
What are the main market barriers for evolocumab?
Cost, patient adherence to injections, and the entry of biosimilars threaten market share; regulatory and reimbursement policies are evolving.
What future indications are under investigation for evolocumab?
Studies are ongoing in familial hypercholesterolemia, statin intolerance, and possibly neurodegenerative diseases.
Key Takeaways
Robust Clinical Evidence: Evolocumab's long-term trials confirm safety and efficacy in cardiovascular risk reduction.
Growing Market: The lipid-lowering therapy market is projected to reach $17.5 billion by 2030, with evolocumab preserving a major share.
Competitive Dynamics: Biosimilar entry and new mechanisms like siRNA threaten to reshape market share; innovation remains critical.
Regulatory and Reimbursement Trends: Policies favor durable outcomes with increasing access, supporting continued growth.
Strategic Positioning: Emphasis on expanding indications, improving adherence, and leveraging combination therapies will optimize evolocumab's market potential.
References
[1] IQVIA Institute. (2022). The Global Use of Medicine in 2022.
[2] MarketsandMarkets. (2022). Lipid-Lowering Therapy Market by Drug Class and Region.
[3] Sabatine MS, et al. (2017). "Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease." New England Journal of Medicine.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
